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IL-17 and TNF Synergistically Modulate Cytokine
Expression while Suppressing Melanogenesis: Potential
Relevance to Psoriasis
Claire Q.F. Wang1, Yemsratch T. Akalu1, Mayte Suarez-Farinas1,2, Juana Gonzalez2, Hiroshi Mitsui1,
Michelle A. Lowes1, Seth J. Orlow3, Prashiela Manga3 and James G. Krueger1
Inflammation-associated pigmentation changes are extremely common, but the etiology underlying this clinical
observation remains elusive. Particularly, it is unclear how the myriad of cytokines known to be involved in
inflammatory skin processes affect epidermal melanocytes. We sought to determine how IL-17 and tumor
necrosis factor (TNF) influence normal human melanocytes, as these two cytokines have been implicated in
various skin diseases. IL-17 and TNF jointly stimulated broad inductions of cytokines, including melanoma
mitogens CXCL1 and IL-8. Moreover, IL-17 and TNF synergistically inhibited pigmentation-related signaling and
melanin production, and induced keratinocyte production of b-defensin 3, an antagonist for melanocortin 1
receptor. When analyzing psoriasis lesions that are known to overexpress IL-17 and TNF, we observed an increase
in melanocyte number and a simultaneous decrease in pigmentation signaling. Furthermore, therapeutic
neutralization of TNF and IL-17 with mAbs resulted in a rapid recovery of pigment gene expression in psoriasis
lesions. These results demonstrate that IL-17 and TNF can affect both the growth and pigment production of
melanocytes, which may contribute to the pigmentation changes associated with psoriasis. These findings may
allow the development of novel therapeutics for pigmentary disorders and bring new insights into the immune
milieu surrounding melanocytes and related neoplasms.
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INTRODUCTION
Psoriasis is an inflammatory skin disease characterized by
keratinocyte hyperplasia, epidermal thickness, and infiltrations
of dermal T cells and leukocytes. A myriad of inflammatory
mediators are overexpressed in psoriasis skin that may con-
tribute to psoriatic skin inflammation, including cytokines
such as tumor necrosis factor (TNF), IFN-g, IL-17, IL-1a,
transforming growth factor-b1, IL-22, and IL-6. Among these
cytokines, the roles of TNF and IL-17 in psoriasis pathogenesis
are best understood (Di Cesare et al., 2009; Krueger et al.,
2012). In recent clinical trials, major disease reversal for
moderate-to-severe psoriasis was attained using IL-17
inhibitors or IL-17 receptor A blockers (Leonardi et al.,
2012; Papp et al., 2012). TNF also has an important role in
the pathogenesis of psoriasis, and TNF inhibitors (e.g.,
etanercept) have been proven to be highly effective in
treatments (Gottlieb et al., 2005). The mechanism of action
of TNF is thought to involve the inhibition of the T helper type
17 cell (Th17) axis (Zaba et al., 2007), suggesting an intricate
relationship between these two pathways.
Interestingly, IL-17 and TNF are also known to interplay and
drive common molecular pathways. Their synergy has been
described in multiple cell types (Shen et al., 2006; Nonaka
et al., 2009; Iyoda et al., 2010; Koenders et al., 2011).
Although IL-17 can induce proinflammatory cytokines by
itself, its effects are vastly increased when cooperating with
TNF (Liang et al., 2006). Our lab and other groups have
previously reported the synergy between IL-17 and TNF in
cultured keratinocytes. The two cytokines synergistically
enhanced the production of signature molecules for psoriasis
disease onset, such as b-defensin 4, S100A7, and LCN2
(Guilloteau et al., 2010; Chiricozzi et al., 2011).
In this study, we sought to examine the effects of IL-17 and
TNF on epidermal melanocytes, either alone or in combina-
tion. Our data revealed a dichotomous effect of IL-17 and TNF
on melanocytes, which not only elicit potentially mitogenic
cytokines but also suppress melanogenesis by downregulating
genes of the pigmentation pathway. We reasoned that this
direct effect of IL-17 and TNF on melanocytes may contribute
to the pigmentary disorders frequently associated with skin
inflammation, and delineating this process may allow the
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development of new targeted therapies for pigmentary dis-
orders. Moreover, our understanding of how IL-17 influences
melanocytes is limited (Kotobuki et al., 2012); our investiga-
tion into the effect of Th17-mediated inflammation on normal
melanocytes brings new insights into the complex layers of
immune interactions surrounding epidermal melanocytes.
RESULTS
Primary human melanocytes form clusters in culture in response
to IL-17 and TNF
To test the effect of IL-17 and TNF, normal human epidermal
melanocytes in serum-free medium were stimulated with
either TNF alone, IL-17 alone, or in combination. At 48 hours,
treated cells formed clusters, and the most striking clustering
effects were observed in cells stimulated with both cytokines
(Supplementary Figure S1a–d online). This clustering effect
was not observed in keratinocytes or fibroblasts (data not
shown). Melanocyte clustering can be completely reversed
3 days after the removal of TNF and IL-17 in the medium
(Supplementary Figure S2 online). Apoptosis and cell viability
assays did not reveal a cytotoxic effect in melanocytes after
cytokine treatment (data not shown).
Microarray profiling of gene expressions confirms IL-17 and TNF
responses in melanocytes
Complementary DNA microarray analysis was performed to
capture broad transcriptional changes in melanocytes treated
with IL-17 and TNF. In a two-dimensional principal compo-
nent analysis plot, the addition of TNF incited major changes
in the gene expression profiles of melanocytes (Supplementary
Figure S3 online). In addition, cells treated with a high dose of
IL-17 produced transcriptional profiles (principal component
analysis) that were distinct from those treated with a low dose,
indicating that the melanocyte response to IL-17 was dose
dependent.
Induction of mitogenic cytokines and growth factor genes
Gene set enrichment analysis of microarray data showed
strong positive enrichment of cytokines and growth factor
genes that may promote an increase in cell number in
melanocytes treated with TNF and IL-17 for 24 hours
(Supplementary Figure S4a and b online). Hierarchical
clustering of the expression profiles of cytokines and growth
factor genes showed most enhanced expressions in cells
costimulated with TNF and IL-17 (Supplementary Figure S4c
and d online). Among the induced genes, several are known
for their growth-promoting effects on melanoma cells and
melanocytes (e.g., CXCL1, CXCL2, CXCL3, IL-6, and IL-8).
Microarray data were validated with quantitative real-time
reverse transcription–PCR (qRT–PCR; Figure 1a), demonstrat-
ing strong inductions of CXCL1, CXCL2, CXCL3, IL-8, brain-
derived neurotrophic factor (BDNF), and CCL20, a Th17
marker gene. Marked synergism was observed in the induction
of CXCL1, CXCL2, CXCL3, BDNF, and IL-8 after costimulation
with TNF and IL-17 (Supplementary Figure S6 online).
Notably, the expression levels of several cytokine receptors
were not seen to be affected, including IL-17RA, IL-17RC,
IL-22R1, IL-1R1, IL-1R2, and so on (data not shown).
Enhanced production of CXCL1 and IL-8
We assessed the level of CXCL1 and IL-8 by FACS-based
intracellular cytokine staining and ELISA-based assays. In cells
treated with both IL-17 and TNF, we observed over 5-fold
increases in the median fluorescence intensity of CXCL1 and
IL-8 versus control (Figure 1b and c). Melanocytes treated with
both IL-17 (200 ng ml1) and TNF secreted nearly 10 times
the amount of CXCL1 and IL-8 into the culture supernatant
compared to controls at 24 hours (Figure 1d and e). Our data
showed that IL-17 is more potent in stimulating CXCL1
production, whereas TNF is more effective in inducing IL-8
production.
Inhibition of pigmentation signaling pathway and melanin
production
Gene set enrichment analysis also showed significant negative
enrichment of melanogenesis genes in the expression profiles
of melanocytes treated with TNF and IL-17 at 24 hours
(Supplementary Figure S5a and c online). On the basis of
recent reviews, a gene set for human skin pigmentation
signaling and melanin synthesis was curated (Baxter et al.,
2009; Sturm, 2009; Rees and Harding, 2012). Hierarchical
clustering of this gene set reveals decreased expression in cells
costimulated with TNF and IL-17 (Figure 2a). Notable among
them are lineage-specific melanocyte transcriptional factors
such as Mitf, SOX10, and Mitf-regulated genes that code for
the rate-limiting enzyme Tyr, Tyrp1, and OCA2, which are
required for efficient maturation of tyrosinase, and Dct,
another catalytic enzyme in melanogenesis. Hierarchical
clustering of genes in the category of melanosome transport
and uptake also shows decreased expressions in cells costi-
mulated with TNF and IL-17 (Supplementary Figure S5b
and d online). In Ingenuity Pathway Analysis system, Mela-
nocyte Development and Pigmentation Signaling pathway
was enriched with significant repression for nearly all mem-
bers of this pathway after treatment with IL-17 and TNF for
24 hours (Figure 2b).
The qRT–PCR for c-kit, MC1R, Mitf, and Dct confirmed
microarray data (Figure 2c). When melanocytes were treated
with IL-17 alone, minimal changes were detected in c-kit, Dct,
and Mitf expressions. However, at 24 hours after treatment
with IL-17 and TNF, the expression of Dct dropped to less than
a quarter of its level in control samples. Marked synergism was
observed in the inhibition c-Kit, MC1R, Mitf, and Dct after
combined treatment with TNF and IL-17 (Supplementary
Figure S6 online).
Tyrosinase is a melanosome membrane glycoprotein that
catalyzes the rate-limiting steps of melanogenesis. A signifi-
cant decrease in tyrosinase levels, as well as in cellular
melanin content, was detected in melanocytes after 48 hours
of exposure to IL-17 and TNF (Figure 2d and e).
Downregulation of pigmentation signaling pathway in lesional
psoriatic skin
Psoriasis lesions contain high levels of IL-17 and TNF,
providing us with a relevant in vivo system to study how skin
inflammation can influence melanocyte biology. We accessed
a meta-analysis-derived psoriasis transcriptome established by
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our group (MAD-3), which combined paired sets of lesional
versus nonlesional skin of over 190 patients (Tian et al., 2012).
A broad inhibition of pigmentation genes was found in this
transcriptome, including cell surface receptors and their
ligands (e.g., Kit Ligand/Stem cell factor, c-Kit, ET-3, ET-1,
and EDNR-B), lineage-specific melanocyte transcriptional
factors (e.g., Mitf, Sox10, and Snai2), and catalytic enzymes
and melanosome proteins involved in melanin synthesis (e.g.,
Dct and OCA2; Figure 3a). This inhibition was confirmed by
qRT–PCR using paired lesional and nonlesional skin
biopsies (n¼ 6). There was a significantly decreased
expression of c-kit, MC1R, Mitf, Sox10 (Po0.01), Dct, and
Tyr (Po0.05; Figure 3b).
Induction of b-defensin 3 in cultured keratinocytes after IL-17 or
TNF treatment
b-Defensin 3 is an antimicrobial peptide that was identified
as a novel antagonist for MC1R (melanocortin 1 receptor)
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Figure 1. IL-17 and tumor necrosis factor (TNF) synergistically induced cytokines and growth factors in cultured melanocytes. (a) Cytokines and growth factor
inductions in melanocytes treated with IL-17 and/or TNF for 24 hours. (b, c) Intracellular cytokine staining shows induction of CXCL1 (chemokine (C-X-C motif)
ligand 1) and IL-8 in melanocytes after treatment with TNF and IL-17 for 24 hours. Median fluorescent intensity is indicated next to each condition. (d) CXCL1
secretion was assessed by ELISA after 24 hours in culture. (e) IL-8 secretion was assessed by electrochemiluminescent (ECL) assay after 24 hours in culture
(*Po0.05; **Po0.01; ***Po0.001 vs. control (Ctrl)). Data represent results from three independent cultures using melanocytes from three different skin donors.
CQF Wang et al.
Cytokine-Mediated Pigmentation Changes
www.jidonline.org 2743
(Beaumont et al., 2012; Swope et al., 2012). It is capable
of inhibiting a-melanocyte-stimulating hormone–induced
increase in the activities of adenylate cyclase and tyrosinase.
Consistent with previous reports (Harder et al., 2001; Hollox
et al., 2008; Peric et al., 2009; Harder et al., 2010), we
detected overexpression of b-defensin 3 in psoriasis lesional
skin (4150-fold increase in mRNA), and a strong tissue
staining (Figure 3c). Keratinocytes are the only source of
b-defensin 3 in human skin (Nomura et al., 2003). We
observed over 2-fold induction of b-defensin 3 mRNA after
24 hours of treatment with IL-17 or TNF in cultured keratino-
cytes (Figure 3d). Meanwhile, we did not detect significant
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Figure 2. Suppression of pigmentation signaling and melanin synthesis after combined IL-17 and tumor necrosis factor (TNF) treatment in melanocytes.
(a) Hierarchical clusters of genes involved in human skin pigmentation signaling and melanin synthesis. (b) Ingenuity Pathway Analysis reveals global inhibition of
Melanocyte Development and Pigmentation Signaling. Arrow indicates genes where the expression was validated by quantitative real-time reverse transcription–
PCR (qRT–PCR) or western blotting. (c) mRNA expression of c-Kit, MC1R, Mitf, and Dct in melanocytes treated with both IL-17 and TNF at 24 hours. (d) Tyrosinase
levels in melanocytes after 48 hours of exposure to IL-17 and TNF. (e) Cellular melanin content in melanocytes treated with IL-17 and TNF for 48 hours. Data show
results from three independent cultures using melanocytes derived from different donors (**Po0.01; ***Po0.001 vs. control (Ctrl)).
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changes in the expression levels of POMC (MSH) and ASIP
(Agouti), the ligand and the other antagonist of M1CR,
respectively.
Increased numbers of melanocytes in psoriasis lesional skin
In a published study of patients with moderate-to-severe
psoriasis who were treated with etanercept (anti-TNF) for 12
weeks (Zaba et al., 2007, 2009), a majority of the patients
developed hyperpigmentation during treatment (Figure 4a).
Melan-A staining and cell counting were performed on paired
biopsies of 10 patients who had favorable responses to
etanercept (nonlesional vs. lesional vs. 12-week recovery).
Lesional psoriasis skin contained almost twice the number of
Melan-Aþ cells per field compared with nonlesional skin
(Po0.001). In some patients, we observed a high density of
Melan-Aþ cells embedded at resolved lesions (Figure 4b).
Melan-A staining on another set of biopsies showed that
psoriatic lesions (n¼11) contained nearly 3-fold Melan-Aþ
cells per field (Po0.001) than normal skin from healthy
volunteers (n¼6; Figure 4c). An ‘‘activated’’ morphology of
melanocytes in psoriasis lesions was observed as the cells
appeared dilated, more dendritic, and their processes elongated.
Double immunofluorescence staining of Ki67, a cell pro-
liferation marker that stains the nuclei, and MART-1 (alter-
native symbol: melan-A), a melanosome surface protein, was
performed (n¼3). In confocal microscopy, Ki67þ /MART-1þ
cells were found in psoriasis lesional skin (Figure 4d), but not
in nonlesional skin or in resolved lesions after 12 weeks of
etanercept treatment.
Recovery of pigmentation signaling in psoriatic lesions after
therapeutic neutralization of IL-17 and TNF
Our group has evaluated the changes in transcriptional
profiles of psoriasis lesional skin after treatment with either
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Figure 5. Rapid recovery of pigmentation genes in psoriasis lesions after therapeutic neutralization of tumor necrosis factor (TNF) and IL-17. (a) Pigmentation
gene expressions (21 probes) in lesional (LS) skin at weeks 0, 1, 2, 4, and 12 were normalized to nonlesional (NL) skin and are shown as average cluster gene
expression±SEM. Progressive recovery of pigmentation genes was observed in patients with good clinical response to etanercept (n¼ 11), but not in
nonresponders (n¼ 4). (b–d) IL-17 neutralization by ixekizumab results in an increase in pigmentation gene expressions in psoriasis lesions compared with
placebo. Fold changes in log2 versus baseline. SEMs are included for genes with multiple complementary DNA (cDNA) probes. (e) Recovery of pigmentation
signaling in psoriasis lesions at week 2 of treatment with either ixekizumab or etanercept (*Po0.05 vs. placebo).
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etanercept (anti-TNF) or ixekinumab (anti-IL-17) (Zaba et al.,
2009; Krueger et al., 2012) These data were mined to assess
pigmentation gene responses of psoriasis patients during
therapy. In the 12-week etanercept study, a group of 15
patients were selected based on sufficient RNA quantity and
quality for performing microarrays, which included 11
responders and 4 nonresponders (Zaba et al., 2009).
Progressive recovery of pigmentation genes was detected in
11 patients who responded to treatment and showed
histological improvement of psoriasis (Figure 5a and
Supplementary Table S1 online). This recovery was not
observed in the lesions of four nonresponders. The expression
levels of pigmentation genes from psoriasis skin lesions in
patients treated with ixekizumab (anti-IL-17) were also exam-
ined. All patients (n¼8) in this trial had successful responses
by week 6. Overall, significant increases in the pigmentation
genes were observed after a 2-week ixekizumab treatment, but
not in the placebo group (Figure 5b–d and Supplementary
Table S2 online). In comparison with etanercept at the same
time point in treatment (week 2), recovery of pigmentation
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signaling following anti-IL-17 treatment appeared to be more
rapid (Figure 5e), which is consistent with a short time course
for effective clinical responses for ixekizumab (6 weeks).
DISCUSSION
Inflammation-associated pigmentary changes are extremely
common. They can be triggered by psoriasis, atopic dermatitis,
and acne vulgaris. Typically, hypopigmentation of the lesions
accompanies active inflammation, but on resolution of the
inflammatory process, patients are at a high risk of developing
hyperpigmentation (Taylor et al., 2009; Vachiramon and
Thadanipon, 2011). One existing hypothesis of hypo-
pigmentation associated with inflammation is that edema,
or the rapid turnover of keratinocytes during epidermal
hyperplasia, will interfere with melanosome transfer to
keratinocytes (Burge et al., 1986; Brenner and Hearing,
2008), but that does not explain the hyperpigmentation
that frequently occurs with disease resolution. Beyond the
case of vitiligo, where an immune response is thought to
be responsible for the destruction of normal melanocytes,
or mastocytosis (Urticaria pigmentosa), where histamine,
leukotrienes, and prostaglandins released by mast cells
are thought to accelerate melanin transfer and increase
pigmentation (Tomita et al., 1989), the etiology under-
lying inflammation-associated pigment disorders remains
elusive.
Here, we revealed the synergistic action of IL-17 and TNF in
regulating melanin production. We previously reported the
presence of Th17 cells in the depigmenting skin of vitiligo
(Wang et al., 2011). In addition, it has been shown that
treatment of melanocytes with agents that induce vitiligo in
the occupational setting causes increased expression of IL-17
and TNF with a concomitant increase in the expression of
cytokines CXCL1, CXCL3, IL-6, IL-8, and CCL20 (Toosi et al.,
2012). Kotobuki et al. (2012) reported that a combination of
four cytokines (i.e., TNF, IL-1b, IL-6, and IL-17) could inhibit
melanin production. However, to our knowledge, the synergy
between IL-17 and TNF in regulating pigment production has
not been reported. IL-17 can act in concert with a number of
cytokines (e.g., IL-1b, TNF, and CXCL1) (Shen and Gaffen,
2008). This synergy can be achieved either by activating
common transcriptional factors or by stabilizing the mRNA of
other cytokines at a post-transcriptional level (Shen et al.,
2006; Hartupee et al., 2007). Our data showed that IL-17 by
itself does not inhibit pigmentation signaling; however, IL-17
can markedly amplify the inhibitory effect of TNF on
melanogenesis.
Psoriasis lesions contained high levels of both TNF and
IL-17, and thus epidermal melanocytes in psoriatic skin are
under the influence of at least these two cytokines. Therapeu-
tic blockade of IL-17 in psoriatic skin may therefore alleviate
the synergistic inhibition of IL-17 and TNF on melanogenesis,
which we observed during ixekizumab (anti-IL-17) treatment.
In the etanercept trial, although psoriasis does not improve
significantly in ‘‘nonresponders,’’ all patients have rapid
inhibition of direct TNF-related genes, such as IL-6 and IL-8
(Zaba et al., 2010). For nonresponders, TNF was most likely
not a primary disease driver, and may not be highly expressed
in the psoriatic lesions of these patients. Hence, TNF blockade
had very little effect on melanocytes in the skin lesions of
nonresponders. In contrast, for the 11 responders, blockade of
TNF resulted in a quick restoration of pigmentation gene
expressions in psoriasis lesions. The rapid reversal of
pigmentation signaling indicates the therapeutic potential of
anti-IL-17 or anti-TNF for treating pigmentary disorders.
However, further prospective studies to monitor changes in
skin pigmentation after localized anti-IL-17 or anti-TNF
treatment are warranted to investigate this possibility.
Although this study focuses only on TNF and IL-17,
pigmentary changes in psoriasis may be modulated by a
myriad of inflammatory mediators that are overexpressed in
psoriasis lesions, including IFN-g, IL-1a, transforming growth
factor-b1, IL-22, and IL-6. Among these cytokines, several are
known to have hypopigmenting effects (TNF, IL-6, IL-1a, and
transforming growth factor-b1), and can independently mod-
ulate the expression of tyrosinase and related enzymes (e.g.,
TYRP1 and DCT) (Swope et al., 1991; Martinez-Esparza et al.,
1999, 2001; Levy et al., 2006; Brenner and Hearing, 2008;
Yang et al., 2008). Our study also focused on the direct effect
of IL-17 and TNF on melanocytes. However, during psoriatic
inflammation, melanocytes are also affected by keratinocyte-
derived secretory products. For instance, IL-17 can induce
several hypopigmenting cytokines in keratinocytes (e.g., TNF,
IL-6, IL-1b, and so on), as well as endothelin-1, CXCL1,
and IL-8, which have growth-stimulating properties.
How keratinocyte-derived inflammatory products influence
melanocytes is an important aspect of biology that we would
like to focus on in future studies.
The observation of increased melanocyte numbers in
psoriasis lesions was unexpected, as the prevailing dogma
suggests that epidermal melanocytes in adult skin are quies-
cent cells and their numbers stay unchanged despite altera-
tions in skin color. Hyperpigmented skin lesions at sites of
inflammation are thought to have no increase in melanocyte
number, although the cells may produce higher amounts of
eumelanin (Brenner and Hearing, 2008). We observed
increased density of melanocytes at the basal layer of the
epidermis during psoriasis resolution, which highly resembled
the pathology of lentigo (Figure 4b). Increased number of
melanocytes, combined with a rapid recovery of pigmentation
function during psoriasis resolution, may lead to an abundant
production of melanin, which will persist in keratinocytes
during treatment until the pigmented keratinocytes are shed.
Hence, a period of postinflammatory hyperpigmentation may
persist for weeks to months, even as melanocyte number
returns to baseline as lesions resolve. This was observed in the
majority of patients treated with etanercept. Our data showed
that IL-17 and TNF induced an array of melanoma and
melanocyte mitogens, including CXCL1, IL-8, IL-6, CXCL2,
CXCL3, and BDNF (Schadendorf et al., 1993; Singh et al.,
1994; Scheibenbogen et al., 1995; Haghnegahdar et al., 2000;
Singh and Varney, 2000; Wang et al., 2000; Mockenhaupt
et al., 2003; Norgauer et al., 2003; Crawford et al., 2008),
which may contribute to a proliferative milieu that supports
melanocyte growth (Figure 6). Neighboring keratinocytes are
known to produce growth stimulators (e.g., endothelin-1,
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CXCL1, IL-6, and IL-8) on IL-17 and TNF stimulation (Venner
et al., 1995; Nograles et al., 2008).
In conclusion, we demonstrate that TNF and IL-17 con-
tribute to the reduction of melanogenesis in psoriasis
lesions. Our data further suggest that these two cytokines
modulate signaling that affects melanocyte proliferation.
Our investigation into the effect of Th17-mediated inflamma-
tion on normal human epidermal melanocytes may thus
help unravel the complex layers of immune interactions
surrounding melanocytes or melanoma, especially
as the protumor or antitumor role of IL-17 is still debated,
and opposing data have been reported in both mice and
human studies (Muranski et al., 2008; Kryczek et al., 2009;
Martin-Orozco et al., 2009). The presence of Ki67þ
melanocytes in psoriasis lesions suggests that immune
infiltration surrounding nevi or melanoma might be a
double-edged sword, where cytokines such as TNF and
IL-17 may contribute to excess melanocyte proliferation,
whereas associated T cells also provide immune surveillance
for melanoma.
MATERIALS AND METHODS
Subjects and skin samples
Skin punch biopsies (6 mm diameter) were obtained from normal
volunteers and psoriasis patients under a protocol approved by
Rockefeller University Institutional Review Board. Written informed
consent was obtained for all studies, and performed in adherence
with the Declaration of Helsinki Principles. See Supplementary
Methods online for details.
Reagents
Supplementary Tables S3 and S4 in Supplementary Material online
lists the sources of primers, antibodies, and their concentrations for
each experiment.
Immunohistochemistry
Primary antibodies for immunohistochemistry are listed in
Supplementary Table S4 online. Standard procedures were used as
previously described (Fuentes-Duculan et al., 2010).
Immunofluorescence
Primary antibodies used for staining are listed in Supplementary Table
S4 online. See Supplementary Methods online for details.
Primary cell culture
Cryopreserved normal human epidermal melanocytes isolated from
juvenile foreskin were purchased from PromoCell (catalog no.
C-12402, Heidelberg, Germany). Primary pooled human keratino-
cytes were obtained from Yale Skin Diseases Research Center core
facility. See Supplementary Methods online for details.
Microarray analysis
Total RNA samples from human melanocytes were hybridized to
Affymetrix Gene Chip Human Genome U133Plus2 (Affymetrix, Santa
Clara, CA). Raw data have been deposited in the National Center for
Biotechnology Information (NCBI) Gene Expression Omnibus reposi-
tory and are accessible through accession number GSE40413. See
Supplementary Methods online for details.
Real-time reverse transcription–PCR (qRT–PCR)
qRT–PCR was performed using Taqman gene expression assay, as
previously published (Chamian et al., 2005). Target gene expressions
were normalized against the housekeeping gene hARP. Primers are
listed in Supplementary Table S3 online.
FACS analysis
Cells were collected 24 hours after cytokine stimulation, and were
incubated with Brefeldin-A (10mg ml 1) for 3 hours before collection,
and stained with the antibodies listed in Supplementary Table S4
online. See Supplementary Methods online for details.
ELISA and electrochemiluminescent assay
For ELISA, Quantikine human CXCL1/GROa kit was used to quantify
CXCL1 level in melanocyte culture supernatant (catalog no. DGR00,
R&D Systems, Minneapolis, MN). For ELISA-based electrochemi-
luminescent assay, human IL-8 Ultra-Sensitive Kit was used to
quantify IL-8 in melanocyte culture supernatant (catalog no.
K151ANC-1, Meso Scale Discovery, Gaithersburg, MD).
Western blotting
Standard procedures were used as previously described (Toosi et al.,
2012).
Melanin content assay
Total cellular melanin content was determined as previously
described (Manga and Orlow, 2001).
Statistical analysis
Data were presented as mean±SD and assessed using repeated-
measures analysis of variance. See Supplementary Methods online for
details.
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